Leukemic Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative diseases (PTLD) following allogeneic hematopoietic stem cell transplantation are extremely rare. We can successfully treat an EBV-associated leukemic lymphoma patient with rituximab, cidofovir, and donor lymphocyte infusion (DLI). In the present case, EBV-specific T cells that were present in the peripheral blood before rituximab administration treatment rapidly increased after DLI in association with a decrease in the EBV-DNA load.
Keywords: Cidofovir; Donor lymphocyte infusion; Epstein–Barr virus; Post-transplant lymphoproliferative disease; Rituximab.
Copyright © 2016 Elsevier B.V. All rights reserved.